Open an account

Sarepta Therapeutics

SRPT · NASDAQ

$19.17+$1.44 (+8.12%)TodayMarket closed ·
Prev close $17.73

About SRPT

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 835 full-time employees. The firm is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, siRNA knockdown therapies, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. The company has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The firm has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS.

Employees
835
Headquarters
Cambridge, Massachusetts
Listed
Jun 4, 1997
Sector
Health Care
Industry
Biotechnology
Website
sarepta.com

SRPT key statistics

Market cap
2.02B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
3.08M
Volume
3.33M
Open price
$17.74
High today
$19.70
Low today
$17.66
52 Week high
$24.68
52 Week low
$14.68

Sarepta Therapeutics (SRPT) at a glance

Sarepta Therapeutics (SRPT) last traded at $19.17, with a market cap of 2.02B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $17.66 and $19.70. The current price is 8.6% above the day's low and 2.7% below its high.

Volume so far is 3.33M shares, in line with the average of 3.08M shares a day.

Over the past year Sarepta Therapeutics has ranged from $14.68 to $24.68, and now sits 45% of the way up that range.

Sarepta Therapeutics met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$0.05 per share against an estimate of $0.2625.

The average analyst price target is $22.58, 17.8% above the current price, from 14 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

43%of 14 analyst ratings say Buy
  • Buy42.9%
  • Hold35.7%
  • Sell21.4%
Price target · 26 analystsAvg $22.58
Low
$5.05
Now
$19.17
High
$39.90

SRPT earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 194.8% on average.

  1. Q3 FY24: reported $0.34 per share against an estimate of -$0.1367
  2. Q4 FY24: reported $1.50 per share against an estimate of $1.93
  3. Q1 FY25: reported -$4.60 per share against an estimate of -$0.9659
  4. Q2 FY25: reported $1.89 per share against an estimate of $0.7657
  5. Q3 FY25: reported -$0.01 per share against an estimate of -$0.8317
  6. Q4 FY25: reported -$3.93 per share against an estimate of -$1.26
  7. Q1 FY26: reported $2.88 per share against an estimate of $1.01
  8. Q2 FY26: reported -$0.05 per share against an estimate of $0.2625

SRPT news

  • Press releaseBusiness Wire

    Sarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual Meeting

  • Press releaseBusiness Wire

    Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT

  • Press releaseBusiness Wire

    Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • Press releaseBusiness Wire

    Sarepta Therapeutics Presents New Data at 2026 World Muscle Society Annual Congress Demonstrating Safety and Clinically Meaningful Functional Benefit of ELEVIDYS (delandistrogene moxeparvovec) in Older Ambulatory Patients with Duchenne

  • Press releaseBusiness Wire

    Sarepta Therapeutics Announces Presentations at 2026 World Muscle Society Annual Congress

  • Press releaseBusiness Wire

    Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 27th Annual Neuromuscular Study Group Scientific Meeting

  • Vandana Singh

    A Rivals Clinical Stumble Sends Sarepta Therapeutics Stock Lower

  • Press releaseBusiness Wire

    Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 Academic Year

Similar companies

Companies in the same industry as Sarepta Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.